Amedisys Inc (AMED)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	US$ in thousands	126,500	78,112	95,400	49,436	40,500	17,956	26,566	67,800	42,694	124,458	91,646	77,344	81,808	112,904	177,278	174,756	30,294	20,757	13,902	10,554
Short-term investments	US$ in thousands	—	—	—	—	40	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	473,721	468,119	462,401	353,050	355,529	367,200	427,372	380,154	374,282	454,349	449,223	456,082	456,337	437,496	442,048	316,106	326,943	314,653	313,007	297,377
Cash ratio		0.27	0.17	0.21	0.14	0.11	0.05	0.06	0.18	0.11	0.27	0.20	0.17	0.18	0.26	0.40	0.55	0.09	0.07	0.04	0.04

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($126,500K + $—K) ÷ $473,721K
= 0.27

The cash ratio of Amedisys Inc. has shown a positive trend over the past eight quarters, increasing from 0.16 in Q2 2022 to 0.36 in Q4 2023. This indicates that the company's ability to cover its current liabilities with cash and cash equivalents has improved significantly.

A cash ratio of 0.36 in Q4 2023 means that Amedisys Inc. had $0.36 in cash and cash equivalents for every dollar of current liabilities. This suggests a strong liquidity position as the company has enough liquid assets to meet its short-term obligations comfortably.

Overall, the increasing trend in the cash ratio reflects positively on Amedisys Inc.'s financial health, indicating a strengthening ability to handle its current obligations using available cash resources.